Serum level of homocysteine, folate and vitamin-B12 in epileptic patients under carbamazepine and sodium valproate treatment: A systematic review and meta-analysis

Iranian Red Crescent Medical Journal

Volumn 15, Issue 3, 2013, Pages 249-253

  Gorjipour, Fazel ^a   Asadi, Yasin ^a,b   Osguei, Nushin K ^c   Effatkhah, Marjan ^a   Samadikuchaksaraei, Ali ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Eposcience Millennium Institute   (Iran)

Author keywords

Adverse effects; Anticonvulsants; Atherosclerosis; Carbamazepine; Epilepsy; Valproic acid

Indexed keywords

CARBAMAZEPINE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; VALPROIC ACID;

ARTICLE; ATHEROGENESIS; DATA ANALYSIS; DISEASE ASSOCIATION; EPILEPSY; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW;

EID: 84895078440     PISSN: 20741804     EISSN: 20741812     Source Type: Journal    
DOI: 10.5812/ircmj.9690     Document Type: Article

References (24)

1. Tan TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang WN, et al. Longterm antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia.2009;50(6):1579-86
2. Jakubus T, Michalska-Jakubus M, Lukawski K, Janowska A, Czuczwar SJ. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol Rep.2009;61(3):411-23
3. Yildiz M, Simsek G, Uzun H, Uysal S, Sahin S, Balci H. Assessment of low-density lipoprotein oxidation, paraoxonase activity, and arterial distensibility in epileptic children who were treated with anti-epileptic drugs. Cardiol Young.2010;20(5):547-54
4. Hamed SA, Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci.2005;98(4):340-53
5. Algin DI, Erdinc OO, Alatas O, Toker A, Colak O, Oner S. Effects of oxcarbazepine on plasma homocysteine, vitamin B12, Folic Acid levels. Noropsikiyatri Ars.2009;46(2):49-51
6. Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B, Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev.2003;25(2):113-5
7. Kurul S, Unalp A, Yis U. Homocysteine levels in epileptic children receiving antiepileptic drugs. J Child Neurol.2007;22(12):1389-92
8. Zeitlhofer J, Doppelbauer A, Tribl G, Leitha T, Deecke L. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Investig.1993;71(7):574-8
9. Hamed SA, Hamed EA, Hamdy R, Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res.2007;74(2-3):183-92
10. Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia.1999;40(3):345-50
11. Deda G, Caksen H, Icagasioglu D. Effect of long-term carbamazepine therapy on serum lipids, vitamin B12 and folic acid levels in children. J Pediatr Endocrinol Metab.2003;16(2):193-6
12. Sener U, Zorlu Y, Karaguzel O, Ozdamar O, Coker I, Topbas M. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure.2006;15(2):79-85
13. Hasan K, Saleh Y, Assaad F. Effects of carbamazepine on serum levels of folic acid and homocysteine. Pan Arab J Neurosurg. 2010;14(1):108-11
14. Algin DI, Erdinç OO, Alataş, Ö., Toker, A., Çolak, Ö., Öner, S.. Effects of oxcarbazepine on plasma homocysteine, vitamin B12, folic acid levels. Noropsikiyatri Arsivi.2009;46(2):49-51
15. Geda G, Caksen H, Icagasioglu D. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy. Acta Neurol Belg.2002;102(3):122-6
16. Fallah S, Nouroozi V, Seifi M, Samadikuchaksaraei A, Aghdashi EM. Influence of oral contraceptive pills on homocysteine and nitric oxide levels: as risk factors for cardiovascular disease. J Clin Lab Anal.2012;26(2):120-3
17. Norouzi V, Seifi M, Fallah S, Korani M, Samadikuchaksaraei A. Effect of oral contraceptive therapy on homocysteine and C-reactive protein levels in women: an observational study. Anadolu Kardiyol Derg.2011;11(8):698-702
18. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract.2012;18 Suppl 1:1-78
19. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis.2012;223(1):1-68
20. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep.2006;8(2):100-6
21. Lopinto-Khoury C, Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol.2010;12(4):300-8
22. Eiris J, Novo-Rodriguez MI, Del Rio M, Meseguer P, Del Rio MC, Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res.2000;41(1):1-7
23. Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health.1997;33(3):242-5
24. Yilmaz E, Dosan Y, Gurgoze MK, Gungor S. Serum lipid changes during anticonvulsive treatment serum lipids in epileptic children. Acta Neurol Belg.2001;101(4):217-20